A carregar...

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS: Patients who failed pri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Holen, Kyle D., Belani, Chandra P., Wilding, George, Ramalingam, Suresh, Volkman, Jennifer L., Ramanathan, Ramesh K., Vasist, Lakshmi S., Bowen, Carolyn J., Hodge, Jeffrey P., Dar, Mohammed M., Ho, Peter T. C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160065/
https://ncbi.nlm.nih.gov/pubmed/20461380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1346-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!